Montelukast - a Treatment Choice for COVID-19

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

March 30, 2020

Study Completion Date

April 20, 2020

Conditions
Covid19SARS-CoV-2 Infection
Interventions
DRUG

Montelukast

An FDA approved medicine to treat asthmatic patients

DRUG

Hydroxychloroquine

An FDA approved antiarthritis drug

DRUG

Ivermectin

An FDA approved anti-parasitic medicine

Trial Locations (2)

54600

Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore

Unknown

Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai

All Listed Sponsors
collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Shaukat Khanum Memorial Cancer Hospital & Research Centre

OTHER

collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Teesside University

OTHER

lead

University of Sargodha

OTHER

NCT04714515 - Montelukast - a Treatment Choice for COVID-19 | Biotech Hunter | Biotech Hunter